Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone: The OPTIMIZE-2 Randomized Clinical Trial.

Hortobagyi GN, Van Poznak C, Harker WG, Gradishar WJ, Chew H, Dakhil SR, Haley BB, Sauter N, Mohanlal R, Zheng M, Lipton A.

JAMA Oncol. 2017 Jul 1;3(7):906-912. doi: 10.1001/jamaoncol.2016.6316.

2.

Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma.

Motzer RJ, Barrios CH, Kim TM, Falcon S, Cosgriff T, Harker WG, Srimuninnimit V, Pittman K, Sabbatini R, Rha SY, Flaig TW, Page R, Bavbek S, Beck JT, Patel P, Cheung FY, Yadav S, Schiff EM, Wang X, Niolat J, Sellami D, Anak O, Knox JJ.

J Clin Oncol. 2014 Sep 1;32(25):2765-72. doi: 10.1200/JCO.2013.54.6911. Epub 2014 Jul 21.

3.

Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer.

Saltz L, Badarinath S, Dakhil S, Bienvenu B, Harker WG, Birchfield G, Tokaz LK, Barrera D, Conkling PR, O'Rourke MA, Richards DA, Reidy D, Solit D, Vakiani E, Capanu M, Scales A, Zhan F, Boehm KA, Asmar L, Cohn A.

Clin Colorectal Cancer. 2012 Jun;11(2):101-11. doi: 10.1016/j.clcc.2011.05.006. Epub 2011 Nov 4.

PMID:
22055112
4.

Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole.

Brufsky AM, Harker WG, Beck JT, Bosserman L, Vogel C, Seidler C, Jin L, Warsi G, Argonza-Aviles E, Hohneker J, Ericson SG, Perez EA.

Cancer. 2012 Mar 1;118(5):1192-201. doi: 10.1002/cncr.26313. Epub 2011 Oct 10.

5.

Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer.

Brufsky A, Harker WG, Beck JT, Carroll R, Tan-Chiu E, Seidler C, Hohneker J, Lacerna L, Petrone S, Perez EA.

J Clin Oncol. 2007 Mar 1;25(7):829-36. Epub 2006 Dec 11.

PMID:
17159193
6.

Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage?

Leonard R, O'Shaughnessy J, Vukelja S, Gorbounova V, Chan-Navarro CA, Maraninchi D, Barak-Wigler N, McKendrick JJ, Harker WG, Bexon AS, Twelves C.

Ann Oncol. 2006 Sep;17(9):1379-85.

7.

Multicenter Phase II study of estramustine phosphate plus weekly paclitaxel in patients with androgen-independent prostate carcinoma.

Vaughn DJ, Brown AW Jr, Harker WG, Huh S, Miller L, Rinaldi D, Kabbinavar F.

Cancer. 2004 Feb 15;100(4):746-50.

8.
10.

Adjusting the dose of intravenous ondansetron plus dexamethasone to the emetogenic potential of the chemotherapy regimen.

Hesketh PJ, Beck T, Uhlenhopp M, Kris MG, Hainsworth JD, Harker WG, Cohen JR, Lester E, Kessler JF, Griffen D, et al.

J Clin Oncol. 1995 Aug;13(8):2117-22.

PMID:
7636556
12.

Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin.

Fujimori A, Harker WG, Kohlhagen G, Hoki Y, Pommier Y.

Cancer Res. 1995 Mar 15;55(6):1339-46.

13.

Altered topoisomerase I expression in two subclones of human CEM leukemia selected for resistance to camptothecin.

Kapoor R, Slade DL, Fujimori A, Pommier Y, Harker WG.

Oncol Res. 1995;7(2):83-95.

PMID:
7579731
14.

A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis.

Hesketh PJ, Harvey WH, Harker WG, Beck TM, Ryan T, Bricker LJ, Kish JA, Murphy WK, Hainsworth JD, Haley B.

J Clin Oncol. 1994 Mar;12(3):596-600.

PMID:
8120559
15.

Peripherally inserted central venous catheters. Low-risk alternatives for ongoing venous access.

Merrell SW, Peatross BG, Grossman MD, Sullivan JJ, Harker WG.

West J Med. 1994 Jan;160(1):25-30.

16.

Single-strand conformational polymorphism analysis of the M(r) 170,000 isozyme of DNA topoisomerase II in human tumor cells.

Danks MK, Warmoth MR, Friche E, Granzen B, Bugg BY, Harker WG, Zwelling LA, Futscher BW, Suttle DP, Beck WT.

Cancer Res. 1993 Mar 15;53(6):1373-9.

17.

Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: a Southwest Oncology Group study.

Bukowski RM, Wolfe M, Levine HS, Crawford DE, Stephens RL, Gaynor E, Harker WG.

J Clin Oncol. 1993 Jan;11(1):161-5.

PMID:
8418229
18.

Isolation, purification, and characterization of two new chemical decomposition products of methylazoxyprocarbazine.

Swaffar DS, Harker WG, Pomerantz SC, Lim HK, Yost GS.

Drug Metab Dispos. 1992 Sep-Oct;20(5):632-42.

PMID:
1358566
19.

Non-enzymatic activation of procarbazine to active cytotoxic species.

Swaffar DS, Pomerantz SC, Harker WG, Yost GS.

Oncol Res. 1992;4(2):49-58.

PMID:
1596582
21.
22.

Multidrug resistance in mitoxantrone-selected HL-60 leukemia cells in the absence of P-glycoprotein overexpression.

Harker WG, Slade DL, Dalton WS, Meltzer PS, Trent JM.

Cancer Res. 1989 Aug 15;49(16):4542-9.

23.

Methylazoxyprocarbazine, the active metabolite responsible for the anticancer activity of procarbazine against L1210 leukemia.

Swaffar DS, Horstman MG, Jaw JY, Thrall BD, Meadows GG, Harker WG, Yost GS.

Cancer Res. 1989 May 1;49(9):2442-7.

24.
25.

Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study.

Harker WG, Meyers FJ, Freiha FS, Palmer JM, Shortliffe LD, Hannigan JF, McWhirter KM, Torti FM.

J Clin Oncol. 1985 Nov;3(11):1463-70.

PMID:
4056840
26.
27.

Dissociation of antitumor potency from anthracycline cardiotoxicity in a doxorubicin analog.

Sikic BI, Ehsan MN, Harker WG, Friend NF, Brown BW, Newman RA, Hacker MP, Acton EM.

Science. 1985 Jun 28;228(4707):1544-6.

PMID:
4012308
28.

Combination chemotherapy for advanced Hodgkin's disease after failure of MOPP: ABVD and B-CAVe.

Harker WG, Kushlan P, Rosenberg SA.

Ann Intern Med. 1984 Oct;101(4):440-6.

PMID:
6206757
29.

Development and characterization of a human sarcoma cell line, MES-SA, sensitive to multiple drugs.

Harker WG, MacKintosh FR, Sikic BI.

Cancer Res. 1983 Oct;43(10):4943-50.

30.

The chemotherapy of bladder carcinoma: systemic therapy.

Harker WG, Torti FM.

Recent Results Cancer Res. 1983;85:37-49. Review. No abstract available.

PMID:
6408717
31.

Chemotherapy of advanced transitional cell carcinoma of the uroepithelium.

Torti FM, Harker WG.

Cancer Chemother Pharmacol. 1983;11 Suppl:S1-4. Review.

PMID:
6357518
32.

Single agent palliative chemotherapy for end-stage Hodgkin's disease.

Mead GM, Harker WG, Kushlan P, Rosenberg SA.

Cancer. 1982 Sep 1;50(5):829-35. No abstract available.

PMID:
6178495
33.

The effect of lithium upon granulocyte production in vitro and in vivo in the mouse.

Rothstein G, Oshita AK, Harker WG, Lonngi G, Christensen RD.

Adv Exp Med Biol. 1980;127:87-98. No abstract available.

PMID:
6250338
34.

Hyperphosphatemia, hypocalcemia, and transient renal failure. Results of cytotoxic treatment of acute lymphoblastic leukemia.

Ettinger DS, Harker WG, Gerry HW, Sanders RC, Saral R.

JAMA. 1978 Jun 9;239(23):2472-4. No abstract available.

PMID:
274588
35.

Enhancement of colony-stimulating activity production by lithium.

Harker WG, Rothstein G, Clarkson D, Athens JW, Macfarlane JL.

Blood. 1977 Feb;49(2):263-7.

PMID:
299818

Supplemental Content

Loading ...
Support Center